Ablynx is preparing to a US filing for its caplacizumab for the rare, life-threatening blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) following additional data from a ...

The European Commission has authorised Cablivi (caplacizumab) as the first therapeutic specifically indicated for the treatment of adults affected by aTTP. The condition, estimated to affect one ...